BlossomHill Therapeutics (BLSM) Corporate presentation summary

Strategic vision and leadership

• Focused on designing novel, orally available precision medicines for cancer with significant unmet needs.

• Leadership team has a strong track record in developing FDA-approved cancer therapies.

• Emphasizes precision drug design based on deep understanding of target biology and protein structure.

Pipeline overview and milestones

• Pipeline includes BH-30643 (OMNI-EGFR inhibitor), BH-30236 (CLK inhibitor), and BH-501284 (pan-KRAS inhibitor).

• Multiple near-term milestones: pivotal Phase 2 for BH-30643 in Q1 2027, IND for BH-501284 in Q1 2027, and Phase 1 data for BH-30236 in 1H 2027.

• Estimated cash runway extends to Q1 2028, with $116M cash at end of Q1 2026.

BH-30643 (OMNI-EGFR inhibitor) clinical progress

• Demonstrated high potency against classical, atypical, and exon20ins EGFR mutations, including C797S resistance.

• Phase 1/2 SOLARA trial shows confirmed responses in C797S-positive NSCLC, with ORR of 53% in chemo-naive and 42% in chemo-treated patients.

• Early activity in TKI-naive patients with 78% ORR and 96% DCR; notable CNS activity and ctDNA clearance.

• Safety profile supports further development, with most adverse events manageable and no grade 5 TRAEs.

• EOP1 meeting planned for Q4 2026 to enable seamless transition to registrational Phase 2 trial.